Abstract:The X-ray structure analysis of three compounds of interest as enzyme substrates is reported. They are the hydrated forms of (I) DL-2-amino-4-arsonobutanoic acid [HO-AsO2--CH2-CH2-CH(NH3+)-CO2H], (II) DL-2-amino-4-phosphonobutanoic acid [HO-PO2--CH2-CH2-CH(NH3+)-CO2H] and the hydrated barium salt of (III) D-3-phosphoglycerate [HO-PO2--O-CH2-CH(OH)-CO2-]. The structures were fully refined to R factors of 0.033, 0.053 and 0.046. For the compounds (I) and (II) the charge distribution was directly determined by lo… Show more
“…However, 2-arsonoacetyl-L-proline was found to be over 2000-fold weaker an inhibitor than 2-phosphonoacetyl-L-proline. The As-C and As-O bond distances in the former are significantly longer than the P-C and P-O distances in the latter (compare DL-2-amino-4-arsonobutanoic acid and DL-2-amino-4-phosphonobutanoic acid; Kamiya et al, .-1983). These greater bond distances may place an arsenic oxygen atom too far to the left of the active-site zinc atom in angiotensin-converting enzyme (see Fig.…”
A series of tetrahedral oxo acids of Group VA and VIA elements and of silicon and boron were examined as inhibitors of angiotensin-converting enzyme. Arsenate is a competitive inhibitor with a Ki of 27 +/- 1 mM, at least 10-fold more potent than phosphate. Dimethylarsinate is a competitive inhibitor with a Ki of 70 +/- 9 mM, 2-fold more potent than dimethylphosphinate. Oxo acids of boron, silicon, antimony, sulphur and selenium are not inhibitors. On the basis of these results and the strong inhibition of this zinc metallopeptidase by substrate analogues containing a tetrahedral phosphorus atom, two substrate analogues containing a tetrahedral arsenic atom were prepared. 2-Arsonoacetyl-L-proline is a competitive inhibitor with a Ki of 18 +/- 7 mM, more than 2000-fold weaker than that of its phosphorus analogue 2-phosphonoacetyl-L-proline. 4-Arsono-2-benzylbutanoic acid is a mixed inhibitor with a Ki of 0.5 +/- 0.2 mM, indistinguishable in potency from its phosphorus analogue 2-benzyl-4-phosphonobutanoic acid.
“…However, 2-arsonoacetyl-L-proline was found to be over 2000-fold weaker an inhibitor than 2-phosphonoacetyl-L-proline. The As-C and As-O bond distances in the former are significantly longer than the P-C and P-O distances in the latter (compare DL-2-amino-4-arsonobutanoic acid and DL-2-amino-4-phosphonobutanoic acid; Kamiya et al, .-1983). These greater bond distances may place an arsenic oxygen atom too far to the left of the active-site zinc atom in angiotensin-converting enzyme (see Fig.…”
A series of tetrahedral oxo acids of Group VA and VIA elements and of silicon and boron were examined as inhibitors of angiotensin-converting enzyme. Arsenate is a competitive inhibitor with a Ki of 27 +/- 1 mM, at least 10-fold more potent than phosphate. Dimethylarsinate is a competitive inhibitor with a Ki of 70 +/- 9 mM, 2-fold more potent than dimethylphosphinate. Oxo acids of boron, silicon, antimony, sulphur and selenium are not inhibitors. On the basis of these results and the strong inhibition of this zinc metallopeptidase by substrate analogues containing a tetrahedral phosphorus atom, two substrate analogues containing a tetrahedral arsenic atom were prepared. 2-Arsonoacetyl-L-proline is a competitive inhibitor with a Ki of 18 +/- 7 mM, more than 2000-fold weaker than that of its phosphorus analogue 2-phosphonoacetyl-L-proline. 4-Arsono-2-benzylbutanoic acid is a mixed inhibitor with a Ki of 0.5 +/- 0.2 mM, indistinguishable in potency from its phosphorus analogue 2-benzyl-4-phosphonobutanoic acid.
“…As V shares high chemical similarity to phosphate, as they are both tetrahedral molecules found in group Va of the periodic table and they share three similar dissociation constants. 9,10 The pK a values of arsenic acid (AsO(OH) 3 ) are 2.26, 6.76, and 11.29, and that of phosphoric acid (PO(OH) 3 ) are 2.16, 7.21, and 12.32. 9 Because of the structural similarity between As V and phosphate, As V is a well-known competitive inhibitor of enzymes that involve phosphate, such as glyceraldehyde-3-phosphate dehydrogenase, as well as the sodium pump and anion exchanger in human erythrocytes.…”
Section: Introductionmentioning
confidence: 99%
“…9,10 The pK a values of arsenic acid (AsO(OH) 3 ) are 2.26, 6.76, and 11.29, and that of phosphoric acid (PO(OH) 3 ) are 2.16, 7.21, and 12.32. 9 Because of the structural similarity between As V and phosphate, As V is a well-known competitive inhibitor of enzymes that involve phosphate, such as glyceraldehyde-3-phosphate dehydrogenase, as well as the sodium pump and anion exchanger in human erythrocytes. 9,11 As V additionally uncouples oxidative phosphorylation by substituting phosphate in ATP, leading to the formation of ADP-arsenate.…”
Section: Introductionmentioning
confidence: 99%
“…9 Because of the structural similarity between As V and phosphate, As V is a well-known competitive inhibitor of enzymes that involve phosphate, such as glyceraldehyde-3-phosphate dehydrogenase, as well as the sodium pump and anion exchanger in human erythrocytes. 9,11 As V additionally uncouples oxidative phosphorylation by substituting phosphate in ATP, leading to the formation of ADP-arsenate. 12 Although As V is generally considered less toxic than other species of arsenic, it undergoes a series of reductions and methylations upon entering the cell, which lead to the generation of other more toxic species such as inorganic As III as well as organic monomethyl or dimethyl metabolites and therefore amplified toxicity.…”
Arsenate is a pentavalent form of arsenic that shares similar chemical properties to phosphate. It has been shown to be taken up by phosphate transporters in both eukaryotic and prokaryotic microbes such as yeast and Escherichia coli. Recently, the arsenate uptake in vertebrate cells was reported to be facilitated by mammalian type II sodium/phosphate transporter with different affinities. As arsenate is the most common form of arsenic exposure in aquatic system, identifying the uptake pathway of arsenate into aquatic animals is a crucial step in the elucidation of the entire metabolic pathway of arsenic. In this study, the ability of a zebrafish phosphate transporter, NaPi-IIb1 (SLC34a2a), to transport arsenate was examined. Our results demonstrate that a type II phosphate transporter in zebrafish, NaPi-IIb1, can transport arsenate in vitro when expressed in Xenopus laevis oocytes. NaPi-IIb1 mediates a high-affinity arsenate transport, with a K(m) of 0.22 mM. The natural substrate of NaPi-IIb1, dibasic phosphate, inhibits arsenate transport. Arsenate transport via NaPi-IIb1 is coupled with Na(+) and exhibits sigmoidal kinetics with a Hill coefficient of 3.24 ± 0.19. Consistent with these in vitro studies, significant arsenate accumulation is observed in all examined zebrafish tissues where NaPi-IIb1 is expressed, particularly intestine, kidney, and eye, indicating that zebrafish NaPi-IIb1 is likely the transport protein that is responsible for arsenic accumulation in vivo.
“…One of these sites is the [3H]AP4 binding site (Butcher et a!., 1983;Monaghan et al, 1983;Bridges et al, 1986), which appears to be the same as the chloride-and calcium-sensitive [ 3H]G1u binding site (Monaghan et at., (Kamiya et al, 1983) shown in two orthogonal views. Note the very similar orientation of all atoms, in particular, the charged amino, carboxyl, and phosphate (L-PSer) or phosphonate (L-AP4) group.…”
Section: Pharmacological Similarity Of L-pser and Lap4mentioning
L-PhOSphoseflne is a membrane metabolite that is elevated in Alzheimer's disease brain. This compound has close structural similarity to L-glutamate. Electrophysiological studies indicate that L-phosphoserme has an acute inhibitory effect, but a delayed excitatory action. A hypothesis is developed based on pharmacological and electrophysiological studies that suggest that the inhibition may be mediated through presyrtaptic inhibition of L-glutamate release or perhaps antagonism of postsynaptic kainic acid receptors. The mechanism of the delayed excitation may lie in the tendency of L-phosphoserine to mimic the action of L-2-amino-4-phosphOnobutyric acid, a blocker of chloride-and calcium-sensitive L-glutamate transport. L-PhosphOserine has also been found to be a competitive antagonist at the N-methyl-o-aspartate recognition site and an antagonist of metabotropic receptor-mediated hydrolysis of inositol phospholipids. Because of these actions, there are several potentially important implications for the elevation of L-phosphoserme in Alzheimer's disease, including production memory impairment through presyn-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.